SCHEMBL8196240

SCHEMBL8196240

O=CNCCC(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.55
HRH1 P35367 2/20 0.55
KCNH2 Q12809 3/20 0.53
MTNR1A P48039 1/20 0.52
MTNR1B P49286 1/20 0.52
CYP3A4 P08684 2/20 0.50
CNR1 P21554 2/20 0.50
OPRM1 P35372 2/20 0.50
EPHX2 P34913 1/20 0.50
CHRM2 P08172 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
CHRM1 P11229 1/20 0.50
SMPD1 P17405 1/20 0.50
DRD1 P21728 1/20 0.50
TBXA2R P21731 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
ADRA1A P35348 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5924683 0.82 RIPK1 (0.47) HTR2AHRH1KCNH2MTNR1AMTNR1B
SCHEMBL23625038 0.82 KDM4E (0.52) MTNR1AMTNR1BOPRM1LMNACYP1A2
SCHEMBL14415780 0.81 CYP19A1 (0.43) HTR2AHRH1KCNH2OPRM1SLC6A4
SCHEMBL11796932 0.80 KCNH2 (0.76) HTR2AHRH1KCNH2MTNR1AMTNR1B
SCHEMBL6877634 0.80 CYP2C19 (0.50) MTNR1AMTNR1BCNR1EPHX2CNR2
SCHEMBL1549013 0.78 GRIN1 (0.50) HTR2AHRH1KCNH2CYP2D6MEN1
SCHEMBL8183916 0.78 EPHX1 (0.47) HTR2AHRH1KCNH2MTNR1AMTNR1B
Hydrochloric Acid SCHEMBL11794831 0.78 KCNH2 (0.73) HTR2AHRH1KCNH2MTNR1AMTNR1B
SCHEMBL10045156 0.77 KCNH2 (0.72) HTR2AHRH1KCNH2SIGMAR1KDM1A
SCHEMBL10045174 0.77 KCNH2 (0.72) HTR2AHRH1KCNH2SIGMAR1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250283094-A1 Modified Nucleosides SOMALOGIC OPERATING CO., INC. (US) 2025-09-11 US disclosed
EP-4323374-A1 MODIFIED NUCLEOSIDES SomaLogic Operating Co., Inc. (US) 2024-02-21 EP disclosed
WO-2022221241-A1 MODIFIED NUCLEOSIDES SOMALOGIC OPERATING CO., INC. (US) 2022-10-20 WO disclosed
EP-2427451-B1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CO LTD (JP) 2019-03-20 EP disclosed
US-6040289-A ACTIVE DRUG TREATING OBESITY DR. KARL THOMAE GMBH (DE) 2000-03-21 US disclosed
US-5962530-A NEUROPEPTIDE Y ANTAGONIST DR. KARL THOMAE GMBH (DE) 1999-10-05 US disclosed
EP-0441226-A1 (cyanomethyl)pyridines useful as PAF antagonists J. URIACH & CIA. S.A. (ES) 1991-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250283094-A1 Modified Nucleosides NT5C3B, PNP, TYMP HTR2A 3172/4885HRH1 4705/4885KCNH2 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.